Alnylam Pharmaceuticals (ALNY) Profit After Tax (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Profit After Tax of $206.0 million for Q1 2026, up 63.53% on a QoQ basis from $126.0 million in Q4 2025, and up 6968.66% year-over-year from $2.9 million in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Profit After Tax (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Profit After Tax history runs 18 years deep, the most recent figure standing at $206.0 million for Q1 2026.
- Quarterly Profit After Tax rose 6968.66% year-over-year to $206.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $524.9 million (up 187.77% YoY) and the FY2025 annual result came in at $328.2 million, up 3045.06% from the prior year.
- Profit After Tax was $206.0 million for Q1 2026 at Alnylam Pharmaceuticals, up from $126.0 million in the prior quarter.
- Across five years, Profit After Tax topped out at $259.3 million in Q3 2025 and bottomed at -$407.5 million in Q3 2022.
- A 5-year average of -$54.0 million and a median of -$65.9 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2025 — Profit After Tax tumbled 766.48% — and 2026, when it surged 6968.66%.
- Alnylam Pharmaceuticals' Profit After Tax stood at -$208.4 million in 2022, then soared by 38.13% to -$128.9 million in 2023, then jumped by 242.16% to $183.3 million in 2024, then tumbled by 31.26% to $126.0 million in 2025, then jumped by 63.53% to $206.0 million in 2026.
- Business Quant data shows ALNY's Profit After Tax at $206.0 million in Q1 2026, $126.0 million in Q4 2025, and $259.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 205.99 Mn |
| Dec 31, 2025 | 125.96 Mn |
| Sep 30, 2025 | 259.26 Mn |
| Jun 30, 2025 | -66.28 Mn |
| Mar 31, 2025 | -3.00 Mn |
| Dec 31, 2024 | 183.25 Mn |
| Sep 30, 2024 | 9.81 Mn |
| Jun 30, 2024 | -7.65 Mn |
| Mar 31, 2024 | -65.94 Mn |
| Dec 31, 2023 | -128.91 Mn |
| Sep 30, 2023 | 152.49 Mn |
| Jun 30, 2023 | -276.02 Mn |
| Mar 31, 2023 | -174.10 Mn |
| Dec 31, 2022 | -208.36 Mn |
| Sep 30, 2022 | -407.48 Mn |
| Jun 30, 2022 | -277.40 Mn |
| Mar 31, 2022 | -240.34 Mn |
| Dec 31, 2021 | -258.46 Mn |
| Sep 30, 2021 | -204.51 Mn |
| Jun 30, 2021 | -189.56 Mn |